

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
ARFORMOTEROL TARTRATE NEB 15MCG/2ML	Formulary Addition	2/1/2024	4	QL,B/D
BREO ELLIPTA INH 50MCG-25MCG	Formulary Addition	2/1/2024	3	QL
ELIGARD INJ 22.5MG	Formulary Addition	2/1/2024	4	QL,PA
ELIGARD INJ 30MG	Formulary Addition	2/1/2024	4	QL,PA
ELIGARD INJ 45MG	Formulary Addition	2/1/2024	4	QL,PA
ELIGARD INJ 7.5MG	Formulary Addition	2/1/2024	4	QL,PA
ENILLORING MIS	Formulary Addition	2/1/2024	4	
FRUZAQLA CAP 1MG	Formulary Addition	2/1/2024	5	QL,PA
FRUZAQLA CAP 5MG	Formulary Addition	2/1/2024	5	QL,PA
INBRIJA CAP 42MG	Formulary Addition	2/1/2024	5	PA
KOURZEQ PST 0.1%	Formulary Addition	2/1/2024	3	
LAGEVRIO CAP 200MG	Formulary Addition	2/1/2024	5	QL
LISDEXAMFETAMINE CAP 20MG	Formulary Addition	2/1/2024	4	

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
LISDEXAMFETAMINE CAP 30MG	Formulary Addition	2/1/2024	4	
LISDEXAMFETAMINE CAP 40MG	Formulary Addition	2/1/2024	4	
LISDEXAMFETAMINE CAP 50MG	Formulary Addition	2/1/2024	4	
LISDEXAMFETAMINE CAP 60MG	Formulary Addition	2/1/2024	4	
LISDEXAMFETAMINE CAP 70MG	Formulary Addition	2/1/2024	4	
LISDEXAMFETAMINE CAP 10MG	Formulary Addition	2/1/2024	4	
LITHIUM SOL 8MEQ/5ML	Formulary Addition	2/1/2024	3	
NEUPRO DIS 1MG/24HR	Formulary Addition	2/1/2024	4	
NEUPRO DIS 2MG/24HR	Formulary Addition	2/1/2024	4	
NEUPRO DIS 3MG/24HR	Formulary Addition	2/1/2024	4	
NEUPRO DIS 4MG/24HR	Formulary Addition	2/1/2024	4	
NEUPRO DIS 6MG/24HR	Formulary Addition	2/1/2024	4	
NEUPRO DIS 8MG/24HR	Formulary Addition	2/1/2024	4	

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
OJJAARA TAB 100MG	Formulary Addition	2/1/2024	5	QL,PA
OJJAARA TAB 150MG	Formulary Addition	2/1/2024	5	QL,PA
OJJAARA TAB 200MG	Formulary Addition	2/1/2024	5	QL,PA
PAXLOVID TAB 150MG-100MG	Formulary Addition	2/1/2024	5	QL
PAXLOVID TAB 300MG-100MG	Formulary Addition	2/1/2024	5	QL
PAZOPANIB TAB 200MG	Formulary Addition	2/1/2024	5	QL,PA
PENTASA CAP 500MG CR	Formulary Addition	2/1/2024	4	QL
QULIPTA TAB 10MG	Formulary Addition	2/1/2024	5	QL,PA
QULIPTA TAB 30MG	Formulary Addition	2/1/2024	5	QL,PA
QULIPTA TAB 60MG	Formulary Addition	2/1/2024	5	QL,PA
SUFLAVE SOL	Formulary Addition	2/1/2024	4	
TRUQAP TAB 160MG	Formulary Addition	2/1/2024	5	QL,PA
TRUQAP TAB 200MG	Formulary Addition	2/1/2024	5	QL,PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
TURQOZ TAB	Formulary Addition	2/1/2024	4	
UBRELVY TAB 100MG	Formulary Addition	2/1/2024	5	QL,PA
UBRELVY TAB 50MG	Formulary Addition	2/1/2024	5	QL,PA
VANFLYTA TAB 17.7MG	Formulary Addition	2/1/2024	5	QL,PA
VANFLYTA TAB 26.5MG	Formulary Addition	2/1/2024	5	QL,PA
VELTASSA POW 16.8GM	Formulary Addition	2/1/2024	4	QL
VELTASSA POW 25.2GM	Formulary Addition	2/1/2024	4	QL
VELTASSA POW 8.4GM	Formulary Addition	2/1/2024	4	QL
YUFLYMA 1PEN KIT 40MG/0.4ML	Formulary Addition	2/1/2024	5	PA
YUFLYMA 2SYR KIT 40MG/0.4ML	Formulary Addition	2/1/2024	5	PA
ZURZUVAE CAP 20MG	Formulary Addition	2/1/2024	5	QL,PA
ZURZUVAE CAP 25MG	Formulary Addition	2/1/2024	5	QL,PA
ZURZUVAE CAP 30MG	Formulary Addition	2/1/2024	5	QL,PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
AKEEGA TAB 100MG/500MG	Formulary Addition	3/1/2024	5	QL,PA
AKEEGA TAB 50MG/500MG	Formulary Addition	3/1/2024	5	QL,PA
AUGTYRO CAP 40MG	Formulary Addition	3/1/2024	5	QL,PA
KALYDECO GRA 5.8MG	Formulary Addition	3/1/2024	5	QL,PA
LISDEXAMFETAMINE DIMESYLATE CHW 10MG	Formulary Addition	3/1/2024	4	
LISDEXAMFETAMINE DIMESYLATE CHW 20MG	Formulary Addition	3/1/2024	4	
LISDEXAMFETAMINE DIMESYLATE CHW 30MG	Formulary Addition	3/1/2024	4	
LISDEXAMFETAMINE DIMESYLATE CHW 40MG	Formulary Addition	3/1/2024	4	
LISDEXAMFETAMINE DIMESYLATE CHW 50MG	Formulary Addition	3/1/2024	4	
LISDEXAMFETAMINE DIMESYLATE CHW 60MG	Formulary Addition	3/1/2024	4	
NORELGESTROMIN/ETHINYL ESTRADIOL 150MCG/35MCG	Formulary Addition	3/1/2024	4	
OGSIVEO TAB 50MG	Formulary Addition	3/1/2024	5	QL,PA
UPTRAVI TAB 1000MCG	Formulary Addition	3/1/2024	5	PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
UPTRAVI TAB 1200MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 1400MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 1600MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 200MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 400MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 600MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI TAB 800MCG	Formulary Addition	3/1/2024	5	PA
UPTRAVI PACK TAB 200MCG/800MCG	Formulary Addition	3/1/2024	5	QL,PA
VIGPODER POW 500MG	Formulary Addition	3/1/2024	5	QL,PA
ZENPEP CAP 60000UNT	Formulary Addition	3/1/2024	3	
BOSULIF CAP 100MG	Formulary Addition	4/1/2024	5	QL,PA
BOSULIF CAP 50MG	Formulary Addition	4/1/2024	5	QL,PA
IWILFIN TAB 192MG	Formulary Addition	4/1/2024	5	QL,PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
LUMRYZ PAK 6GM	Formulary Addition	4/1/2024	5	QL,PA
LUMRYZ PAK 7.5GM	Formulary Addition	4/1/2024	5	QL,PA
LUMRYZ PAK 9GM	Formulary Addition	4/1/2024	5	QL,PA
LUMRYZ PKG 4.5GM	Formulary Addition	4/1/2024	5	QL,PA
PENBRAYA INJ	Formulary Addition	4/1/2024	3	QL
RISPERIDONE INJ 12.5MG	Formulary Addition	4/1/2024	4	
RISPERIDONE INJ 25MG ER	Formulary Addition	4/1/2024	4	
RISPERIDONE INJ 37.5MG	Formulary Addition	4/1/2024	4	
RISPERIDONE INJ 50MG ER	Formulary Addition	4/1/2024	5	
SODIUM SULFATE/POTASSIUM SULFATE/MAGNESIUM SULFATE SOL	Formulary Addition	4/1/2024	3	
SYNJARDY XR TAB 10MG-1000MG	Formulary Addition	4/1/2024	3	QL
SYNJARDY XR TAB 12.5MG-1000MG	Formulary Addition	4/1/2024	3	QL
SYNJARDY XR TAB 25MG-1000MG	Formulary Addition	4/1/2024	3	QL

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
SYNJARDY XR TAB 5MG-1000MG	Formulary Addition	4/1/2024	3	QL
XALKORI CAP 150MG	Formulary Addition	4/1/2024	5	PA
XALKORI CAP 20MG	Formulary Addition	4/1/2024	5	PA
XALKORI CAP 50MG	Formulary Addition	4/1/2024	5	PA
CYCLOSERINE CAP 250MG	Formulary Addition	5/1/2024	4	
HEATHER TAB 0.35MG	Formulary Addition	5/1/2024	4	
IXCHIQ INJ	Formulary Addition	5/1/2024	3	QL
MIFEPRISTONE TAB 300MG	Formulary Addition	5/1/2024	5	QL,PA
ROZLYTREK PAK 50MG	Formulary Addition	5/1/2024	5	QL,PA
TRIENTINE CAP 500MG	Formulary Addition	5/1/2024	5	QL,PA
XOLAIR INJ 150MG/ML	Formulary Addition	5/1/2024	5	PA
XOLAIR PREFILLED INJ 300MG/2ML	Formulary Addition	5/1/2024	5	PA
XOLAIR AUTO-INJECTOR INJ 300MG/2ML	Formulary Addition	5/1/2024	5	PA



**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
XOLAIR INJ 75MG/0.5ML	Formulary Addition	5/1/2024	5	PA
CLINDAMYCIN GEL 1%	Formulary Addition	6/1/2024	3	QL
NITROGLYCERIN OIN 0.4%	Formulary Addition	6/1/2024	4	QL
THEOPHYLLINE TAB 100MG ER	Formulary Addition	6/1/2024	2	
THEOPHYLLINE TAB 200MG ER	Formulary Addition	6/1/2024	2	
YUFLYMA 1-PEN KIT 80MG/0.8ML	Formulary Addition	6/1/2024	5	PA
YUFLYMA 2-SYRINGE KIT 20MG/0.2ML	Formulary Addition	6/1/2024	5	PA
YUFLYMA CD/UC/HS STARTER KIT 80MG/0.8ML	Formulary Addition	6/1/2024	5	PA
JYLAMVO SOL 2MG/ML	Formulary Addition	7/1/2024	4	PA
RYALTRIS SPR 665MCG-25MCG	Formulary Addition	7/1/2024	4	
VRAYLAR CAP 1.5MG	Removal of Utilization Management	7/1/2024	5	PA Removed
VRAYLAR CAP 3MG	Removal of Utilization Management	7/1/2024	5	PA Removed
VRAYLAR CAP 4.5MG	Removal of Utilization Management	7/1/2024	5	PA Removed

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
VRAYLAR CAP 6MG	Removal of Utilization Management	7/1/2024	5	PA Removed
XCOPRI TAB 25MG	Formulary Addition	7/1/2024	5	QL,PA
YARGESA CAP 100MG	Formulary Addition	7/1/2024	5	PA
CYLTEZO PREFILLED KIT 40/0.4ML	Formulary Addition	8/1/2024	5	QL,PA
CYLTEZO AUTO-INJECTOR KIT 40/0.4ML	Formulary Addition	8/1/2024	5	QL,PA
CYLTEZO KIT CROHNS	Formulary Addition	8/1/2024	5	PA
CYLTEZO PSORIASIS/UVEITIS KIT 40MG/0.4ML	Formulary Addition	8/1/2024	5	PA
FASENRA INJ 10MG/0.5ML	Formulary Addition	8/1/2024	5	PA
INGREZZA CAP 40MG	Formulary Addition	8/1/2024	5	QL,PA
INGREZZA CAP 60MG	Formulary Addition	8/1/2024	5	QL,PA
INGREZZA CAP 80MG	Formulary Addition	8/1/2024	5	QL,PA
LIBERVANT MIS 10MG	Formulary Addition	8/1/2024	5	QL,PA
LIBERVANT MIS 12.5MG	Formulary Addition	8/1/2024	5	QL,PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
LIBERVANT MIS 15MG	Formulary Addition	8/1/2024	5	QL,PA
LIBERVANT MIS 5MG	Formulary Addition	8/1/2024	5	QL,PA
LIBERVANT MIS 7.5MG	Formulary Addition	8/1/2024	5	QL,PA
VARENICLINE TAB 1MG	Formulary Addition	8/1/2024	3	
XDEMZY DRO 0.25%	Formulary Addition	8/1/2024	5	QL
MYHIBBIN SUS 200MG/ML	Formulary Addition	9/1/2024	5	B/D
OGSIVEO TAB 100MG	Formulary Addition	9/1/2024	5	QL,PA
OGSIVEO TAB 150MG	Formulary Addition	9/1/2024	5	QL,PA
OJEMDA SUS 25MG/ML	Formulary Addition	9/1/2024	5	QL,PA
OJEMDA TAB 100MG	Formulary Addition	9/1/2024	5	QL,PA
SCSEMBLIX TAB 100MG	Formulary Addition	9/1/2024	5	QL,PA
DRIZALMA CAP 20MG DR	Formulary Addition	10/1/2024	4	QL,ST
DRIZALMA CAP 30MG DR	Formulary Addition	10/1/2024	4	QL,ST

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
DRIZALMA CAP 40MG DR	Formulary Addition	10/1/2024	4	QL,ST
DRIZALMA CAP 60MG DR	Formulary Addition	10/1/2024	4	QL,ST
ENTRESTO CAP 15MG-16MG	Formulary Addition	10/1/2024	3	QL
ENTRESTO CAP 6MG-6MG	Formulary Addition	10/1/2024	3	QL
L-GLUTAMINE POW 5GM	Formulary Addition	10/1/2024	5	PA
NALOXONE HCL SOL 0.4MG/ML	Formulary Addition	10/1/2024	2	
NEXLETOL TAB 180MG	Formulary Addition	10/1/2024	3	QL,PA
NEXLIZET TAB 180/10MG	Formulary Addition	10/1/2024	3	QL,PA
SOTYKTU TAB 6MG	Formulary Addition	10/1/2024	5	QL,PA
TORPENZ TAB 10MG	Formulary Addition	10/1/2024	5	PA
TORPENZ TAB 2.5MG	Formulary Addition	10/1/2024	5	PA
TORPENZ TAB 5MG	Formulary Addition	10/1/2024	5	PA
TORPENZ TAB 7.5MG	Formulary Addition	10/1/2024	5	PA

**FORMULARY ADDITIONS UPDATE:**

The following summary describes recent changes to the formulary effective October 1, 2024

<b>FORMULARY ADDITIONS, REDUCTIONS IN PREFERRED OR TIERED COST-SHARING STATUS, OR REMOVAL OF UTILIZATION MANAGEMENT TO AN EXISTING FORMULARY DRUG</b>				
<b>Drug Name</b>	<b>Description of Change</b>	<b>Effective Date of Change</b>	<b>Tier</b>	<b>Utilization Management Notes</b>
TYENNE INJ 162MG	Formulary Addition	10/1/2024	5	QL,PA
TYENNE INJ 162MG/0.9ML	Formulary Addition	10/1/2024	5	QL,PA
XOLREMDI CAP 100MG	Formulary Addition	10/1/2024	5	QL,PA

Plans are insured through UnitedHealthcare Insurance Company or one of its affiliated companies, a Medicare Advantage organization with a Medicare contract and a Medicare-approved Part D sponsor. Enrollment in the plan depends on the plan's contract renewal with Medicare.

**QL** = Quantity Limit, **PA** = Prior Authorization, **ST** = Step Therapy, **B/D** = Medicare Part B/D determination

**AER** = Aerosol, **CAP** = Capsule, **CON** = Concentrate, **CRE** = Cream, **DRO** = Drops, **ER** = Extended Release, **ENE** = Enema, **GRA** = Granules, **INH** = Inhalation, **INJ** = Injection, **LOT** = Lotion, **NEB** = Nebulizer, **ODT** = Orally Disintegrating, **OIN** = Ointment, **OP** = Ophthalmic, **POW** = Powder, **SHA** = Shampoo, **SOL** = Solution, **SPR** = Spray, **SUB** = Sublingual, **SUP** = Suppository, **SUS** = Suspension, **TAB** = Tablet, **CHW** = Chewable

[<OVEX3385284\_000>]

Formulary ID# 24005

Y0066\_111223\_140152 File & Use 12282011